These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 39134463

  • 1. Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors on major liver outcomes in metabolic dysfunction-associated steatotic liver disease.
    Shen TH, Aby ES, Vock D, Farley JF.
    Diabetes Obes Metab; 2024 Nov; 26(11):5116-5125. PubMed ID: 39134463
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong.
    Au PCM, Tan KCB, Lam DCL, Cheung BMY, Wong ICK, Kwok WC, Sing CW, Cheung CL.
    JAMA Netw Open; 2023 Jan 03; 6(1):e2251177. PubMed ID: 36648944
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes.
    Paik JM, Tesfaye H, Curhan GC, Zakoul H, Wexler DJ, Patorno E.
    JAMA Intern Med; 2024 Mar 01; 184(3):265-274. PubMed ID: 38285598
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
    Lee S, Zhou J, Leung KSK, Wai AKC, Jeevaratnam K, King E, Liu T, Wong WT, Chang C, Wong ICK, Cheung BMY, Tse G, Zhang Q.
    Cardiovasc Drugs Ther; 2023 Jun 01; 37(3):561-569. PubMed ID: 35142921
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DM.
    Khera R, Aminorroaya A, Dhingra LS, Thangaraj PM, Pedroso Camargos A, Bu F, Ding X, Nishimura A, Anand TV, Arshad F, Blacketer C, Chai Y, Chattopadhyay S, Cook M, Dorr DA, Duarte-Salles T, DuVall SL, Falconer T, French TE, Hanchrow EE, Kaur G, Lau WCY, Li J, Li K, Liu Y, Lu Y, Man KKC, Matheny ME, Mathioudakis N, McLeggon JA, McLemore MF, Minty E, Morales DR, Nagy P, Ostropolets A, Pistillo A, Phan TP, Pratt N, Reyes C, Richter L, Ross JS, Ruan E, Seager SL, Simon KR, Viernes B, Yang J, Yin C, You SC, Zhou JJ, Ryan PB, Schuemie MJ, Krumholz HM, Hripcsak G, Suchard MA.
    J Am Coll Cardiol; 2024 Sep 03; 84(10):904-917. PubMed ID: 39197980
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes : A Target Trial Emulation Study.
    Tang H, Lu Y, Donahoo WT, Shao H, Shi L, Fonseca VA, Guo Y, Bian J, Guo J.
    Ann Intern Med; 2024 Aug 03; 177(8):1004-1015. PubMed ID: 39008852
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Association of acute increases in serum creatinine with subsequent outcomes in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor or dipeptidyl peptidase-4 inhibitor.
    Chan YH, Chao TF, Chen SW, Kao YW, Huang CY, Chu PH.
    Eur Heart J Qual Care Clin Outcomes; 2023 Jun 21; 9(4):397-407. PubMed ID: 35797996
    [Abstract] [Full Text] [Related]

  • 17. Safety of sodium-glucose co-transporter-2 inhibitors on amputation across categories of baseline cardiovascular disease and diuretics use in patients with type 2 diabetes.
    Park S, Jeong HE, Bea S, Yu OHY, Cho YM, You SC, Man KKC, Shin JY.
    Diabetes Obes Metab; 2023 Nov 21; 25(11):3248-3258. PubMed ID: 37503763
    [Abstract] [Full Text] [Related]

  • 18. Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes.
    Richardson TL, Halvorson AE, Hackstadt AJ, Hung AM, Greevy R, Grijalva CG, Elasy TA, Roumie CL.
    Ann Intern Med; 2023 Jun 21; 176(6):751-760. PubMed ID: 37155984
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Lower Risks of New-Onset Hepatocellular Carcinoma in Patients With Type 2 Diabetes Mellitus Treated With SGLT2 Inhibitors Versus DPP4 Inhibitors.
    Chou OHI, Ning J, Chan RNC, Chung CT, Huang H, Ng K, Dee EC, Lee S, Kaewdech A, Chow AKM, Man NK, Liu T, Jing F, Cheung BMY, Tse G, Zhou J.
    J Natl Compr Canc Netw; 2024 Jun 21; 22(2 D):. PubMed ID: 38862004
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.